Abstract 593751 The disclosure relates to compounds according to the formula (I) that are 2-pyridin-2-yl-pyrazol-3(2H)-one derivatives their preparation and their therapeutic uses and activity as HIF activators Disclosed are compounds according to the formula (I): R is a -SO2-NR3R4 group, a hydrogen atom, a halogen atom, a -halogeno(C1-C5)alkyl group, a -CO2R5 group or a -SO2-R4 group； R1 is a heterocycloalkyl group containing no nitrogen atoms, a -W-(C3-C6)cycloalkyl group, a -W-aryl group, a -W-heteroaryl group, a -W-heterocycloalkyl group, a -W-COOR5 group, a -W-CONR5R6 group； R2 is a hydrogen atom, a -(C1-C5)alkyl group, a -(C1-C5)alkylene-0-(C1-C5)alkyl group, a -halogeno(C1-C5)alkyl group, a -W-COOR5 group, a -W-C(O)NHR5 group or a -W-C(O)-NR5R6 group； n is 0, 1 or 2； W is a -(C1-C5)alkylene- group- or a -(C3-C6)cycloalkylene- group； R3 and R4, identical or different, are, independently from one another, a hydrogen atom, a -(C1-C5)alkyl group, a -(C3-C6)cycloalkyl group, a -(C1-C5)alkylene-O-(C1-C5)alkyl group, an aryl, a -CH2-aryl group, a heteroaryl, a heterocycloalkyl, a -W-OH group, a -W-CHOH-CH2OH group, a -W-CO2R5 group, a -W-NR5R6 group or a -W-O-(CH2)n-aryl group； or else R3 and R4 jointly form a heterocycloalkyl group with the nitrogen atom that supports them； R5 and R6, identical or different, are, independently from one another, a hydrogen atom, a -(C1-C5)alkyl group or a (C1-C5)halogenoalkyl group, as well as to a method for preparing same and their use in treatment of cardiac conditions. Compounds disclosed include: N-cyclopentyl-N-ethyl-6-[5-oxo-4-(pyridin-3-ylmethyl)-2,5-dihydro-1H-pyrazol-1-yl]pyridine-3-sulfonamide； N-(2,2-dimethylpropyl)-N-methyl-6-[5-oxo-4-(pyridin-3-ylmethyl)-2,5-dihydro-1H-pyrazol-1-yl]pyridine-3-sulfonamide； 6-(4-benzyl-5-oxo-2,5-dihydro-1H-pyrazol-1-yl)-N-cyclopentyl-N-[3-(dimethylamino)propyl]-pyridine-3-sulfonamide hydrochloride； And 4-(2-chlorobenzyl)-5-methyl-2-[5-(trifluoromethyl)pyridin-2-yl]-1,2-dihydro-3H-pyrazol
